GHO Capital Acquires U.K.-based Quotient Clinical
Quotient Clinical is based in Nottingham, U.K., where formulation development, real-time Good Manufacturing Practice services, and early clinical trials are performed at the same facility.
Quotient Clinical, a provider of early stage and drug development services, has been acquired by healthcare investor GHO Capital.
Quotient Clinical is based in Nottingham, U.K., where formulation development, real-time Good Manufacturing Practice services, and early clinical trials are performed at the same facility. It employs over 280 staff and offers a range of support services, from study set-up to data analysis and reporting. Over 75% of its customers are in the U.S. or mainland Europe.
“We are delighted to be partnering with GHO Capital for the next phase of our growth,” said Mark Egerton, Chief Executive Officer of Quotient Clinical. “In the past few years, we have proven the benefits of Translational Pharmaceutics (the company’s own platform), and its adoption by an ever increasing number of customers continues to drive our business growth. Partnering with GHO Capital, we will now work to expand our differentiated service portfolio and extend our operational footprint internationally.”
Read the full release.
Telemedicine Considerations When Conducting Decentralized Clinical Trials
January 14th 2025Compliance with state telemedicine requirements is imperative, as not only will most clinical trial sponsors contractually require such compliance, but non-compliance may also subject the practitioner to licensure violations and liability.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
